[go: up one dir, main page]

WO2017002765A1 - Composition pour réduire les calories - Google Patents

Composition pour réduire les calories Download PDF

Info

Publication number
WO2017002765A1
WO2017002765A1 PCT/JP2016/069034 JP2016069034W WO2017002765A1 WO 2017002765 A1 WO2017002765 A1 WO 2017002765A1 JP 2016069034 W JP2016069034 W JP 2016069034W WO 2017002765 A1 WO2017002765 A1 WO 2017002765A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
calorie
reducing
cyclic dipeptide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2016/069034
Other languages
English (en)
Japanese (ja)
Inventor
伸哉 富貴澤
寿栄 鈴木
斉志 渡辺
満広 ▲ゼイ▼田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Priority to JP2017526343A priority Critical patent/JPWO2017002765A1/ja
Publication of WO2017002765A1 publication Critical patent/WO2017002765A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link

Definitions

  • the present invention relates to a composition for reducing calories. More specifically, the present invention relates to a calorie reducing composition containing a cyclic dipeptide as an active ingredient, a low calorie composition containing the cyclic dipeptide, and a method for producing the same.
  • Patent Document 1 is obtained by mechanically stirring a gelatinized product obtained by adding more than 0.5 times the amount of water to rice containing high amylose rice and / or medium amylose rice and heat-treating it. It is disclosed that the rice gel can be used as an alternative food material or an alternative food for diet or calorie reduction by substituting part or all of protein, oil and fat, and grains other than rice originally contained in the food material or food.
  • dipeptides in which two amino acids are bonded are attracting attention as functional substances. Dipeptides can add physical properties and new functions not found in simple amino acids, and are expected to have a range of applications beyond amino acids. Among these, diketopiperazine, which is a cyclic dipeptide, is known to have various physiological activities, and various studies have been conducted.
  • Patent Document 2 discloses that by heating an aqueous solution containing at least one of a linear dipeptide and a linear tripeptide containing at least one proline or hydroxyproline as a constituent, at least one proline or It is disclosed that a cyclic dipeptide containing hydroxyproline as a constituent can be easily produced. Specifically, for example, cyclo (Gly-Pro) is efficiently produced by heat treatment (90 ° C., 24 hours) of a linear dipeptide, glycylproline (Gly-Pro) in an aqueous solution ( Conversion rate 92.6%).
  • An object of the present invention is to provide a calorie reducing material containing a cyclic dipeptide as an active ingredient, a calorie reducing composition containing the cyclic dipeptide, and a method for producing the same.
  • the present invention relates to the following [1] to [6].
  • [1] A calorie reducing composition containing a cyclic dipeptide or a salt thereof.
  • [2] A food or drink comprising the calorie reducing composition according to [1].
  • [3] A method for producing a food or drink comprising using the calorie reducing composition according to [1].
  • [4] A method for reducing calories of the composition, which comprises blending a cyclic dipeptide or a salt thereof with the composition.
  • a method for reducing caloric intake comprising a step of administering an effective amount of a cyclic dipeptide or a salt thereof to an individual who needs to reduce caloric intake.
  • the composition for reducing calories of the present invention has an excellent effect that it can be used as a material for reducing calories, and a composition containing this is effective for dieting.
  • the present invention is characterized by using a cyclic dipeptide in order to reduce calorie intake.
  • a cyclic dipeptide is excellent in permeability from the intestinal tract and is not easily degraded by peptidases and the like.
  • cyclic dipeptides have two amino acid terminal moieties linked via an amide bond (ie, cyclic dipeptides have a cyclic structure formed by the amide bond between the amino terminus and the carboxy terminus) Therefore, the lipophilicity is higher than that of a linear dipeptide (particularly, a linear dipeptide having the same kind of amino acid composition) in which a carboxy group or amino group, which is a polar group, is exposed at the molecular terminal portion. Therefore, the cyclic dipeptide is excellent in gastrointestinal permeability, membrane permeability, and hence absorption, as compared with a linear dipeptide. This is also clear from the results of compound permeation tests using rat inverted intestinal tracts reported in the past (J.
  • cyclic dipeptides are less susceptible to peptidases in the body than linear peptides due to their cyclic structure, and therefore are not decomposed into free amino acids after absorption from the digestive tract.
  • the cyclic dipeptide is not used for protein synthesis, but is excreted outside the body mainly as an unchanged form or a conjugate of a water-soluble molecule such as glucuronic acid, and does not serve as an energy source.
  • these assumptions do not limit the present invention.
  • the calorie reducing material of the present invention is a calorie reducing composition containing a cyclic dipeptide or a salt thereof as an active ingredient.
  • the calorie reducing material of the present invention is also referred to as a calorie reducing composition.
  • the cyclic dipeptide or its salt used in order to reduce intake calories may be collectively described as the cyclic dipeptide of the present invention.
  • cyclic dipeptide of the present invention examples include cycloglycylproline [Cyclo (Gly-Pro)], cycloprolylhydroxyproline [Cyclo (Pro-Hyp)], cyclohydroxyprolylglycine [Cyclo (Hyp-Gly)].
  • Cyclovalylserine [Cyclo (Val-Ser)], Cycloarginylglycine [Cyclo (Arg-Gly)], Cycloalanylvaline [Cyclo (Ala-Val)], Cycloglutaminylserine [Cyclo (Gln-Ser)] And the like. You may use these individually by 1 type or in combination of 2 or more types.
  • the salt of the cyclic dipeptide refers to any pharmacologically acceptable salt of the cyclic dipeptide (including inorganic salts and organic salts), for example, sodium salt, potassium salt of the cyclic dipeptide, Calcium salt, magnesium salt, ammonium salt, hydrochloride, sulfate, nitrate, phosphate, organic acid salt (acetate, citrate, maleate, malate, oxalate, lactate, succinate, Fumarate, propionate, formate, benzoate, picrate, benzenesulfonate, etc.).
  • the cyclic dipeptide of the present invention can be prepared according to a method known in the art, and a commercially available product can also be used. For example, it may be produced by a chemical synthesis method, an enzymatic method, or a microbial fermentation method, or may be synthesized by dehydrating and cyclizing a linear peptide. For example, a heat-treated product obtained by heat-treating plant components and / or animal components can be suitably used.
  • the plant component used in the present invention is not particularly limited as long as it contains a linear dipeptide, tripeptide, or oligopeptide.
  • a plant extracts selected from the group consisting of soybean, malt, barley, wheat, coffee, black beans, sesame, and tea can be mentioned.
  • the extraction method a known method can be used, and extraction may be performed so as to include the above-described linear peptide.
  • a commercial item can be used.
  • the animal component used in the present invention is not particularly limited as long as it contains a linear dipeptide, tripeptide, or oligopeptide. Specific examples include one or more selected from the group consisting of collagen peptides, milk, whey, casein, and placenta extract. These origin animals are not particularly limited. These animal components may be prepared according to known techniques, or commercially available products may be used.
  • Examples of the heat treatment method of the plant component and / or animal component include a method of heating the plant component and / or animal component in a solution or in a solid phase.
  • Examples of the solution medium used in the heat treatment include water, organic solvents, and mixtures thereof.
  • Examples of the organic solvent include ethanol and hexane.
  • the mixing ratio in the case of mixing with water is not particularly limited.
  • the pH of the solution during the heat treatment and the concentration of the raw material used for heating are not particularly limited, and can be appropriately set according to the type of medium as long as the heating can be performed.
  • the heating temperature is not generally set depending on the type of raw material or medium to be heated, but is exemplified by 100 to 170 ° C. in both heating in a solution and heating in a solid phase. 110 to 150 ° C. is preferable.
  • the heating time can be appropriately set depending on the heating temperature, and examples thereof include 0.25 to 10 hours.
  • Cyclo (Gly-Pro) after preparing a collagen peptide containing the linear dipeptide Gly-Pro in an aqueous solution of an arbitrary concentration, A material containing Cyclo (Gly-Pro) can be obtained by heating at about 170 ° C. for about 0.25 to 10 hours.
  • ingredients are not particularly limited as long as the calorie reducing material of the present invention contains the aforementioned cyclic dipeptide or a salt thereof.
  • the content of cyclic dipide or a salt thereof in the dry solid is not generally set depending on the raw material to be heated, but is 0.01% (w / w)% or more It is preferable that it is 0.1 w / w% or more.
  • the content in soybean is 0.02 to 0.30 w / w%
  • the content in barley malt is 0.01 to 0.20 w / w%
  • the content in tea The amount is 0.02 to 0.30 w / w%
  • the content of collagen peptide is about 1.0 to 30 w / w%.
  • content of cyclic dipetide or its salt can be measured by the HPLC method, for example.
  • the content of the cyclic dipeptide or its salt per Brix in the liquid is not set unconditionally depending on the raw material used for heating, but is preferably 1.0 ppm / Brix or more. More preferably, it is 10 ppm / Brix or more.
  • Cyclo Gly-Pro
  • the content in soybean is 2.0-30 ppm / Brix
  • the content in barley malt is 1.0-20 ppm / Brix
  • the content in tea is 2.0- 30 ppm / Brix
  • the collagen peptide content is about 100 to 3000 ppm / Brix.
  • ppm per Brix means an amount determined by a value corresponding to a mass percentage of a sucrose solution at 20 ° C. (an aqueous solution containing only sucrose as a solute).
  • ppm used herein means ppm of weight / volume (w / v), and 1.0 ppm / Brix is 0.1 mg / wt when the specific gravity of the solvent is 1. Converted to mL and converted to 0.01% by weight.
  • content of cyclic dipetide or its salt per Brix can be measured using HPLC or a saccharimeter, for example.
  • the cyclic dipeptide from which the cyclic dipeptide or its salt is eliminated suppresses metabolism by peptidase in the living body. Therefore, when the ingested cyclic dipeptide is 100 wt%, at least 35 % By weight, preferably 50% by weight or more, more preferably 90% by weight or more is excreted in the urine as an unchanged form or a conjugate of a water-soluble molecule such as glucuronic acid.
  • the upper limit is not set and may be 100% by weight or less.
  • one or more treatments selected from the group consisting of filtration, centrifugation, concentration, ultrafiltration, lyophilization, pulverization, and fractionation May be prepared according to a known method, or may be formulated as it is, or may be prepared in a form that can be used for raw materials such as pharmaceuticals, quasi drugs, and foods and drinks. Therefore, the said processed material is contained as one aspect
  • the present invention also provides a composition containing the calorie reducing material of the present invention, that is, the calorie reducing composition of the present invention.
  • the composition can be suitably used as a low calorie composition.
  • the composition may be simply referred to as the composition of the present invention. Therefore, such a composition is an embodiment of the calorie reducing material of the present invention, and a composition containing a cyclic dipeptide or a salt thereof is included in the present invention.
  • the low calorie is preferably less than 5 kcal / 100 mL (100 g in the case of solid matter), more preferably less than 4 kcal / 100 mL (100 g in the case of solid matter), and more preferably 3 kcal / 100 mL (solid matter). Means less than 100 g).
  • the number of calories is basically a value calculated according to “Analysis method of nutritional components and the like in nutrition labeling standards” published in relation to the health promotion method.
  • the low-calorie composition of the present invention can be suitably used for the purpose of reducing caloric intake or dieting, or for diseases that require a caloric intake-reducing action, for example, pharmaceuticals, quasi drugs, or foods and beverages It is used as a form of Therefore, as a mode of the low calorie composition of the present invention, a pharmaceutical, a quasi drug, or a food or drink can be mentioned.
  • the disease requiring the action of reducing caloric intake is not particularly limited as long as it has a therapeutic effect by reducing caloric intake.
  • examples include diabetes, hypertension, obesity, hyperuricemia, dyslipidemia, arteriosclerosis and the like.
  • the composition of the present invention is extremely useful for symptom improvement and prevention of diseases that require a caloric intake reduction action. That is, the composition of the present invention can be used as a food for specified health use, a nutritional functional food, a special-purpose food, a functional indication food, a health supplement (supplement), for example, for the purpose of preventing or ameliorating the above-mentioned diseases. , Diet, calorie reduction, or the indication that it is used for prevention and / or improvement of metabolic syndrome. It is a very useful composition for those who are concerned about blood pressure, those who are concerned about blood pressure, those who are concerned about blood sugar after meals, those who are concerned about uric acid level, and the like.
  • composition of the present invention is not limited to a composition mainly intended to reduce calories, but feels hunger and stress due to dietary restrictions by replacing some of the components with the calorie reducing material of the present invention. Therefore, it is possible to achieve prevention or amelioration of the above diseases while obtaining a feeling of fullness after eating.
  • the content of the cyclic dipeptide of the present invention or a salt thereof in the composition of the present invention cannot be set unconditionally depending on the type of cyclic dipeptide, its preparation conditions, post-treatment conditions, etc., from the viewpoint of exerting its effects
  • it is 0.01 w / w% or more, More preferably, it is 0.1 w / w% or more, More preferably, it is 1.0 w / w% or more.
  • the upper limit is not particularly set, and as an alternative component such as dipeptides, tripeptides, oligopeptides, proteins, lipids, carbohydrates, etc. can do.
  • composition of the present invention can be appropriately contained as a component other than the cyclic dipeptide of the present invention or a salt thereof as long as the effects of the present invention are not impaired. Moreover, it is also possible to improve the stability and added value of the composition by using other useful components in combination. Their content is not particularly limited as long as it does not impair the effects of the present invention.
  • the composition of the present invention may be prepared according to a known production method by mixing the raw material for calorie reduction of the present invention with its raw materials when preparing a known pharmaceutical product, quasi-drug, or food or drink. Moreover, you may prepare by adding the raw material for calorie reduction of this invention to a well-known well-known food-drink, and melt
  • a well-known pharmaceutical, a quasi-drug, or food-drinks may contain the said cyclic dipeptide or its salt originally, and it mixes and prepares suitably in the range with the effect of this invention. can do.
  • composition of the present invention is not particularly limited.
  • carbonated drinks natural fruit juices, fruit juice drinks, soft drinks (including fruit juices), fruit drinks, fruit foods with fruit grains, vegetable drinks, soy milk, Soy milk beverages, coffee beverages, tea beverages, jelly beverages, powdered beverages, concentrated beverages, sports beverages, nutritional beverages, alcoholic beverages and other favorite beverages, nutritional foods, supplements, pills, hard capsules, soft capsules, tablets Sugar-coated tablets, intraoral quick disintegrating tablets, chewable tablets (chewable tablets), effervescent tablets, troches, film-coated tablets, etc.].
  • the present invention also provides a method for producing a low calorie composition, characterized in that the calorie reducing material of the present invention is used as a raw material of the composition of the present invention.
  • the amount used, the addition time, and the addition method are not particularly limited, and other components added and blended are also used without limitation.
  • the amount used and the method of addition can also be appropriately selected according to known techniques. Specifically, for example, carriers, bases, and / or additives that are usually used in the pharmaceutical field, food field, and the like can be appropriately blended within a range that achieves the object of the present invention.
  • a method for reducing the calories of the composition can be provided by blending the calorie reducing material of the present invention into the composition.
  • the raw material for reducing calories of the present invention is used as a raw material of the composition, the previous item can be referred to.
  • the present invention provides a method for reducing caloric intake, which comprises administering to the individual in need of reducing caloric intake the cyclic dipeptide of the present invention or a salt thereof, or an effective amount of the low calorie composition of the present invention.
  • a method for reducing caloric intake which comprises administering to the individual in need of reducing caloric intake the cyclic dipeptide of the present invention or a salt thereof, or an effective amount of the low calorie composition of the present invention.
  • the effective amount cannot be generally set, and can be appropriately adjusted according to a desired calorie reduction amount.
  • Quantitative analysis was performed using calibration curve data prepared using a blank urine sample and a standard aqueous solution. Calculate the urinary excretion of Cyclo (Gly-Pro) from the obtained urinary Cyclo (Gly-Pro) concentration and urine weight, and calculate the urinary excretion of Cyclo (Gly-Pro) as Cyclo (Gly-Pro) The urinary excretion rate was calculated by dividing by the dose. The results are shown in Table 2. As a reference example, a linear dipeptide Gly-Pro was also tested in the same manner, and the results are also shown. ⁇ Analysis conditions for LC-MS / MS> [HPLC conditions] The following solvents were used for the mobile phase, and the following gradient conditions were applied.
  • Example 2 Examination of urinary excretion rate after administration of cyclic dipeptide Cyclo (Gly-Tyr) Same as Example 1 except that Cyclo (Gly-Tyr) is used as the cyclic dipeptide and urine recovery time is set to 72 hours The test was conducted. The sample used was a Cyclo (Gly-Tyr) standard (Kobe Natural Products Chemicals).
  • the analysis was performed using LC-MS / MS (API5000, ABSCIEX), and the analysis target substances were Cyclo (Gly-Tyr) and Cyclo (Gly-Tyr) -GlcA. (Glucuron conjugate, according to a known synthesis method).
  • the conditions for HPLC and MS analysis were as described below.
  • Quantitative analysis was performed using calibration curve data prepared using a blank urine sample and a standard aqueous solution. Calculate the urinary excretion amount from the concentration of urinary Cyclo (Gly-Tyr) unchanged substance and metabolite (glucuronic acid conjugate) and the urine weight, and the urinary excretion amount in terms of substance (mole) was divided by the dose to calculate the urinary excretion rate.
  • the results are shown in Table 4. ⁇ Analysis conditions for LC-MS / MS> [HPLC conditions] The following solvents were used for the mobile phase, and the following gradient conditions were applied.
  • compositions containing the cyclic dipeptide of the present invention or a salt thereof will be exemplified. These compositions can be prepared according to known methods.
  • Production Example 1 Powder for dissolution at time of use As shown in Table 5 below, a composition containing the cyclic dipeptide of the present invention or a salt thereof and other excipients such as ceramide raw material, elastin peptide, proteoglycan, vitamin C, dextrin and the like. A powder for dissolution (6.5 g) at the time of use was manufactured by weighing and mixing to be uniform. When the obtained powder was dissolved in water, all of them had good dispersibility, and were suitable as dissolving beverages at the time of use.
  • Production Example 2 Tablet As shown in Table 6 below, a composition containing the cyclic dipeptide of the present invention or a salt thereof and a mixture containing other raw materials were granulated and molded by a conventional method to obtain tablets.
  • Production Example 3 Collagen Peptide-Containing Beverage A beverage having the following composition was obtained using a composition containing the cyclic dipeptide of the present invention or a salt thereof obtained by a known method using collagen peptide as a raw material.
  • composition for reducing calorie of the present invention is mainly absorbed as a conjugate of a water-soluble molecule such as unchanged substance or glucuronic acid without the cyclic dipeptide contained therein being efficiently absorbed in the living body and being decomposed into free amino acids. Since it is excreted as it is, it is useful for, for example, dieting, calorie reduction, or prevention and / or improvement of metabolic syndrome.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pour réduire les calories contenant un dipeptide cyclique ou un sel de celui-ci, et un aliment ou une boisson comprenant ladite composition pour réduire les calories. La composition pour réduire les calories de l'invention est telle que le dipeptide cyclique qu'elle comprend est absorbé de manière efficace par un corps biologique, n'est pas dégradée par un acide aminé libre, et est principalement éliminée telle quelle en tant que conjugué de molécules hydrosolubles d'une substance non altérée ou d'un acide glucuronique, ou similaire, et se révèle ainsi avantageuse, notamment, pour un régime, une réduction de calories, ou la prévention et/ou l'amélioration du syndrome métabolique.
PCT/JP2016/069034 2015-06-30 2016-06-27 Composition pour réduire les calories Ceased WO2017002765A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017526343A JPWO2017002765A1 (ja) 2015-06-30 2016-06-27 カロリー低減用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-131554 2015-06-30
JP2015131554 2015-06-30

Publications (1)

Publication Number Publication Date
WO2017002765A1 true WO2017002765A1 (fr) 2017-01-05

Family

ID=57608856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/069034 Ceased WO2017002765A1 (fr) 2015-06-30 2016-06-27 Composition pour réduire les calories

Country Status (3)

Country Link
JP (1) JPWO2017002765A1 (fr)
TW (1) TW201717785A (fr)
WO (1) WO2017002765A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119837994A (zh) * 2025-01-16 2025-04-18 广州中医药大学(广州中医药研究院) 一种环状二肽在改善或治疗血脂异常相关疾病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010166911A (ja) * 2008-12-26 2010-08-05 Suntory Holdings Ltd 環状ジペプチド含有飲料
WO2014200000A1 (fr) * 2013-06-10 2014-12-18 サントリーホールディングス株式会社 Extrait de plante contenant de la dicétopipérazine, et son procédé de production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010166911A (ja) * 2008-12-26 2010-08-05 Suntory Holdings Ltd 環状ジペプチド含有飲料
WO2014200000A1 (fr) * 2013-06-10 2014-12-18 サントリーホールディングス株式会社 Extrait de plante contenant de la dicétopipérazine, et son procédé de production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIAKI KIGUCHI ET AL.: "Simultaneous determination of aspartame, its epimer and their degradation products in foods by HPLC and LC/MS", JAPANESE JOURNAL OF FOOD CHEMISTRY AND SAFETY, vol. 17, no. 2, 2010, pages 130 - 135, XP055342297, ISSN: 1341-2094 *
HAYASAKA, FUMITAKA ET AL.: "PRODUCTION METHOD FOR THE FUNCTIONAL CYCLIC DIPEPTIDE DERIVED FROM COLLAGEN", THE 51ST JAPANESE PEPTIDE SYMPOSIUM KOEN YOSHISHU, 2014, pages 55 *
MIZUMA, TAKASHI ET AL.: "Intestinal Absorption of Stable Cyclic Glycylphenylalanine: Comparison with the Linear Form", J. PHARM. PHRMACOL., vol. 49, 1997, pages 1067 - 1071, XP055342299 *
PRODOLLOET, JACQUES ET AL.: "Determination of Aspartame and Its Major Decomposition Products in Foods", JOURNAL OF AOAC INTERNATIONAL, vol. 76, no. 2, 1993, pages 275 - 282 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119837994A (zh) * 2025-01-16 2025-04-18 广州中医药大学(广州中医药研究院) 一种环状二肽在改善或治疗血脂异常相关疾病中的应用

Also Published As

Publication number Publication date
JPWO2017002765A1 (ja) 2018-04-12
TW201717785A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
JP6796487B2 (ja) 環状ジペプチド高含有組成物
AU2015275507A1 (en) Cyclic dipeptide-containing composition
JP6669750B2 (ja) 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物
CN107847545B (zh) 含有环状二肽及甜味剂的组合物
JP6772133B2 (ja) Ｇｌｐ−２分泌促進用組成物
TWI701031B (zh) 含有胺基酸及環狀二肽之組成物
JP5885784B2 (ja) 経口組成物
WO2017002765A1 (fr) Composition pour réduire les calories
WO2017014153A1 (fr) Composition contre l'obésité comprenant un dipeptide cyclique
JP6770515B2 (ja) 血圧降下用組成物
US20120040895A1 (en) Peptide availability
JP2019151572A (ja) Ｆｇｆ分泌促進用組成物
US20220330595A1 (en) Angiotensin-converting enzyme inhibitor, blood pressure-lowering agent, and beverages and food products
JP6687619B2 (ja) メラニン凝集ホルモン受容体拮抗用組成物
JP4673071B2 (ja) 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法
US20120028902A1 (en) Peptide availability
HK1250630B (zh) 含有环状二肽及甜味剂的组合物
TW201127391A (en) Cholecystokinin secretion promoter
HK1230626A1 (en) Cyclic dipeptide-containing composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16817873

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017526343

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16817873

Country of ref document: EP

Kind code of ref document: A1